Skip to main content

ULTRA-DD

Innovative Medicines Initiative LogoEfpia logoEuropean Commission Research and Innovation logo

Search

  • Overview
    • Objectives and disease focus
    • Deliverables
      • Executive Summary 2020 Report
      • Executive Summary 2019 Report
      • Executive Summary 2018 Report
    • Organisation
      • Scientific Committee
      • Leadership
    • Participants
    • News
    • Contact
  • Tissue Platforms
    • Diseases
    • Cell Assay Datasets
  • Probes
    • Chemical Probes
    • Biological probes
  • Antibodies
  • Structures
  • ChromoHub
  • Publications

Inhibition of Microsomal Prostaglandin E Synthase-1 in Cancer-Associated Fibroblasts Suppresses Neuroblastoma Tumor Growth.

  • Read more about Inhibition of Microsomal Prostaglandin E Synthase-1 in Cancer-Associated Fibroblasts Suppresses Neuroblastoma Tumor Growth.

Kock, A., Larsson, K., Bergqvist, F., Eissler, N., Elfman, L., Raouf, J., … Kogner, P. (2018). Inhibition of Microsomal Prostaglandin E Synthase-1 in Cancer-Associated Fibroblasts Suppresses Neuroblastoma Tumor Growth. EBioMedicine, 32, 84–92.

The Bone-Protecting Efficiency of Chinese Medicines Compared With Western Medicines in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Comparative Studies.

  • Read more about The Bone-Protecting Efficiency of Chinese Medicines Compared With Western Medicines in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Comparative Studies.

Cai, X., Chen, X. M., Xia, X., Bao, K., Wang, R. R., Peng, J. H., … Huang, Q. C. (2018). The Bone-Protecting Efficiency of Chinese Medicines Compared With Western Medicines in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Comparative Studies. Frontiers in pharmacology, 9, 914.

A DNA-Encoded Library of Chemical Compounds Based on Common Scaffolding Structures Reveals the Impact of Ligand Geometry on Protein Recognition.

  • Read more about A DNA-Encoded Library of Chemical Compounds Based on Common Scaffolding Structures Reveals the Impact of Ligand Geometry on Protein Recognition.

Favalli, N., Biendl, S., Hartmann, M., Piazzi, J., Sladojevich, F., Gräslund, S., … Neri, D. (2018). A DNA-Encoded Library of Chemical Compounds Based on Common Scaffolding Structures Reveals the Impact of Ligand Geometry on Protein Recognition. ChemMedChem, 13(13), 1303–1307. 

Patients with anti-Jo1 antibodies display a characteristic IgG Fc-glycan profile which is further enhanced in anti-Jo1 autoantibodies.

  • Read more about Patients with anti-Jo1 antibodies display a characteristic IgG Fc-glycan profile which is further enhanced in anti-Jo1 autoantibodies.

Fernandes-Cerqueira, C., Renard, N., Notarnicola, A., Wigren, E., Gräslund, S., Zubarev, R. A., … Lundström, S. L. (2018). Patients with anti-Jo1 antibodies display a characteristic IgG Fc-glycan profile which is further enhanced in anti-Jo1 autoantibodies. Scientific reports, 8(1), 17958. doi:10.1038/s41598-018-36395-z.

AP-SWATH Reveals Direct Involvement of VCP/p97 in Integrated Stress Response Signaling Through Facilitating CReP/PPP1R15B Degradation.

  • Read more about AP-SWATH Reveals Direct Involvement of VCP/p97 in Integrated Stress Response Signaling Through Facilitating CReP/PPP1R15B Degradation.

Hülsmann, J., Kravic, B., Weith, M., Gstaiger, M., Aebersold, R., Collins, B., Meyer, H. (2018). AP-SWATH Reveals Direct Involvement of VCP/p97 in Integrated Stress Response Signaling Through Facilitating CReP/PPP1R15B Degradation. Molecular & Cellular Proteomics, 17(7), 1295-1307.

Creation of a Novel Class of Potent and Selective MutT Homologue 1 (MTH1) Inhibitors Using Fragment-Based Screening and Structure-Based Drug Design.

  • Read more about Creation of a Novel Class of Potent and Selective MutT Homologue 1 (MTH1) Inhibitors Using Fragment-Based Screening and Structure-Based Drug Design.

Rahm F, Viklund J, Trésaugues L, Ellermann M, Giese A, Ericsson U, ... Andersson M. (2018). Creation of a Novel Class of Potent and Selective MutT Homologue 1 (MTH1) Inhibitors Using Fragment-Based Screening and Structure-Based Drug Design. Journal of Medicinal Chemistry, 61(6), 2533-2551.

Discovery of a novel allosteric inhibitor scaffold for polyadenosine-diphosphate-ribose polymerase 14 (PARP14) macrodomain 2.

  • Read more about Discovery of a novel allosteric inhibitor scaffold for polyadenosine-diphosphate-ribose polymerase 14 (PARP14) macrodomain 2.

Moustakim, M., Riedel, K., Schuller, M., Gehring, A. P., Monteiro, O. P., Martin, S. P., … Brennan, P. E. (2018). Discovery of a novel allosteric inhibitor scaffold for polyadenosine-diphosphate-ribose polymerase 14 (PARP14) macrodomain 2. Bioorganic & medicinal chemistry, 26(11), 2965–2972.

Effects of FKBP12 and Type II BMP Receptors on Signal Transduction by ALK2 Activating Mutations Associated with Genetic Disorders.

  • Read more about Effects of FKBP12 and Type II BMP Receptors on Signal Transduction by ALK2 Activating Mutations Associated with Genetic Disorders.

Machiya A, Tsukamoto S, Ohte S, Kuratani M, Fujimoto M, Kumagai K, ... Katagiri T. (2018). Effects of FKBP12 and Type II BMP Receptors on Signal Transduction by ALK2 Activating Mutations Associated with Genetic Disorders. Bone, 111, 101-108.

New Opportunities for Kinase Drug Repurposing and Target Discovery.

  • Read more about New Opportunities for Kinase Drug Repurposing and Target Discovery.

Knapp S. (2018). New Opportunities for Kinase Drug Repurposing and Target Discovery. British Journal of Cancer, 118(7), 936-937.

Identifying Small Molecule Binding Sites for Epigenetic Proteins at Domain-Domain Interfaces.

  • Read more about Identifying Small Molecule Binding Sites for Epigenetic Proteins at Domain-Domain Interfaces.

Bowkett, D., Talon, R., Tallant, C., Schofield, C., von Delft, F., Knapp, S., … Brennan, P. E. (2018). Identifying Small-Molecule Binding Sites for Epigenetic Proteins at Domain-Domain Interfaces. ChemMedChem, 13(10), 1051–1057.

Pagination

  • Next page ››
Subscribe to 2018
The ULTRA-DD project is supported by the Innovative Medicines Initiative Joint Undertaking (IMI JU) under grant agreement n° [115766], resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution. This website reflects only the author’s views and neither IMI nor the European Commission is liable for any use that may be made of the information contained therein.
This website is licensed under a CC-BY licence | Accessibility